Tovetumab
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) [1][2].
Product Specifications
CAS Number
1243266-04-7
Product Name Alternative
MEDI-575
UNSPSC
12352203
Target
PDGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tovetumab.html
Purity
99.49
Solubility
10 mM in DMSO
Smiles
[Tovetumab]
Molecular Weight
(145.39 kDa)
References & Citations
[1]Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23 (1) :4. |[2]Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83 (6) :1247-56.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
PDGFRα
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041231-500 1x 500 µL
Eosinophil Peroxidase (AHE-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400531-100 1x 100 µL
VEGF-R2 / CD309 / Flk-1 / KDR3 (DC101), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682053-500 1x 500 µL
Nucleophosmin (Acute Myeloid Leukemia Marker) (NA24), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details